Skip to main content
SpringerLink
Log in

Statins and Neuromuscular Disease

  • Chapter
  • First Online:
Statin-Associated Muscle Symptoms

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 473 Accesses

Abstract

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMG-CoA reductase) and have by definition a pleiotropic effect on both target and off-target cells due to their influence on downstream intermediaries of cholesterol biosynthesis.

Also, since multiple metabolic pathways are potentially affected by statins, it is reasonable to expect possible negative interactions in patients who are known to have underlying neuromuscular disorders or who have developed a newly diagnosed neuromuscular condition. A growing number of case reports have found an association between statin exposure and the expression of inherited neuromuscular diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. Neurology. 2004;63(11):2188.

    Article  Google Scholar 

  2. Oh SJ, Dhall R, Young A, Morgan MB, Lu L, Claussen GC. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008;38(3):1101–7.

    Article  CAS  Google Scholar 

  3. Purvin V, Kawasaki A, Smith KH, Kesler A. Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Medicine (Baltimore). 2006;85(2):82–5.

    Article  Google Scholar 

  4. Milani M, Ostlie N, Wang W, Conti-Fine BM. T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci. 2003;998:284–307.

    Article  CAS  Google Scholar 

  5. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420(6911):78–84.

    Article  CAS  Google Scholar 

  6. Krendel DA, Sanders DB, Massey JM. Single fiber electromyography in chronic progressive external ophthalmoplegia. Muscle Nerve. 1987;10(4):299–302.

    Article  CAS  Google Scholar 

  7. Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet. 2007;369(9578):2031–41.

    Article  CAS  Google Scholar 

  8. Sorensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3(4):413–7.

    Article  Google Scholar 

  9. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004–9.

    Article  CAS  Google Scholar 

  10. Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: An analysis of individual case safety reports from vigibase. Drug Saf. 2007;30(6):515–25.

    Article  Google Scholar 

  11. Colman E, Szarfman A, Wyeth J, Mosholder A, Jillapalli D, Levine J, et al. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA’s spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf. 2008;17(11):1068–76.

    Article  Google Scholar 

  12. Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler. 2008;9(4):223–8.

    Article  CAS  Google Scholar 

  13. Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med. 2006;166(14):1519–24.

    Article  CAS  Google Scholar 

  14. Pierno S, De Luca A, Tricarico D, Roselli A, Natuzzi F, Ferrannini E, et al. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther. 1995;275(3):1490–6.

    CAS  PubMed  Google Scholar 

  15. Sonoda Y, Gotow T, Kuriyama M, Nakahara K, Arimura K, Osame M. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve. 1994;17(8):891–7.

    Article  CAS  Google Scholar 

  16. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med. 1993;94(1):109–10.

    Article  CAS  Google Scholar 

  17. Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome. A case report. Eur Neurol. 2007;57(4):232–5.

    Article  Google Scholar 

  18. Karaa A, Kriger J, Grier J, Holbert A, Thompson JL, Parikh S, et al. Mitochondrial disease patients’ perception of dietary supplements’ use. Mol Genet Metab. 2016;119(1-2):100–8.

    Article  CAS  Google Scholar 

  19. Deichmann R, Lavie C, Andrews S. Coenzyme q10 and statin-induced mitochondrial dysfunction. Ochsner J. 2010;10(1):16–21.

    PubMed  PubMed Central  Google Scholar 

  20. La Guardia PG, Alberici LC, Ravagnani FG, Catharino RR, Vercesi AE. Protection of rat skeletal muscle fibers by either L-carnitine or coenzyme Q10 against statins toxicity mediated by mitochondrial reactive oxygen generation. Front Physiol. 2013;4:103.

    Article  Google Scholar 

  21. Mickelson JR, Louis CF. Malignant hyperthermia: Excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. Physiol Rev. 1996;76(2):537–92.

    Article  CAS  Google Scholar 

  22. Baker SK, Samjoo IA. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci. 2008;35(1):8–21.

    Article  Google Scholar 

  23. Guis S, Figarella-Branger D, Mattei JP, Nicoli F, Le Fur Y, Kozak-Ribbens G, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum. 2006;55(4):551–7.

    Article  CAS  Google Scholar 

  24. Lamb GD. Rippling muscle disease may be caused by “silent” action potentials in the tubular system of skeletal muscle fibers. Muscle Nerve. 2005;31(5):652–8.

    Article  Google Scholar 

  25. Pol A, Martin S, Fernandez MA, Ingelmo-Torres M, Ferguson C, Enrich C, et al. Cholesterol and fatty acids regulate dynamic caveolin trafficking through the Golgi complex and between the cell surface and lipid bodies. Mol Biol Cell. 2005;16(4):2091–105.

    Article  CAS  Google Scholar 

  26. Baker SK, Tarnopolsky MA. Sporadic rippling muscle disease unmasked by simvastatin. Muscle Nerve. 2006;34(4):478–81.

    Article  CAS  Google Scholar 

  27. Reuser AJ, Kroos MA, Hermans MM, Bijvoet AG, Verbeet MP, Van Diggelen OP, et al. Glycogenosis type II (acid maltase deficiency). Muscle Nerve Suppl. 1995;3:S61–9.

    Article  CAS  Google Scholar 

  28. Voermans NC, Lammens M, Wevers RA, Hermus AR, van Engelen BG. Statin-disclosed acid maltase deficiency. J Intern Med. 2005;258(2):196–7.

    Article  CAS  Google Scholar 

  29. Andreu AL, Nogales-Gadea G, Cassandrini D, Arenas J, Bruno C. McArdle disease: molecular genetic update. Acta Myol. 2007;26(1):53–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Lorenzoni PJ, Silvado CE, Scola RH, Luvizotto M, Werneck LC. McArdle disease with rhabdomyolysis induced by rosuvastatin: case report. Arq Neuropsiquiatr. 2007;65(3B):834–7.

    Article  Google Scholar 

  31. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681–90.

    Article  CAS  Google Scholar 

  32. Wieser T. Carnitine palmitoyltransferase II deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews((R)). Seattle: University of Washington; 1993.

    Google Scholar 

  33. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34(2):153–62.

    Article  CAS  Google Scholar 

  34. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology. 2002;58(9):1333–7.

    Article  CAS  Google Scholar 

  35. Baker SK. Quantitative strength testing in Charcot-Marie-Tooth patients exposed to lipid-lowering therapy. 59th annual meeting of the mucle & Nerve; 10/2012. Muscle & Nerve. 2012. p. 662–3.

    Google Scholar 

  36. Harper CR, Jacobson TA. Evidence-based management of statin myopathy. Curr Atheroscler Rep. 2010;12(5):322–30.

    Article  CAS  Google Scholar 

  37. Brunham LR, Ruel I, Aljenedil S, Rivière J-B, Baass A, Tu JV, et al. Canadian cardiovascular society position statement on familial hypercholesterolemia: update 2018. Can J Cardiol. 2018;34(12):1553–63.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Divisions of Physical Medicine & Neurology, Neuromuscular Disease Clinic, McMaster University Medical Centre, McMaster University, Hamilton, ON, Canada

    A. Alsolaihim

  2. Department of Medicine, Divisions of Physical Medicine & Neurology, Neuromuscular Disease Clinic, Neuromuscular Diseases, McMaster University Medical Centre, Hamilton, ON, Canada

    S. K. Baker

Authors
  1. A. Alsolaihim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. K. Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. K. Baker .

Editor information

Editors and Affiliations

  1. Hartford Hospital, University of Connecticut, Hartford, CT, USA

    Paul D. Thompson

  2. Hartford Hospital, University of Connecticut, Hartford, CT, USA

    Beth A. Taylor

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Alsolaihim, A., Baker, S.K. (2020). Statins and Neuromuscular Disease. In: Thompson, P., Taylor, B. (eds) Statin-Associated Muscle Symptoms. Contemporary Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-33304-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-33304-1_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-33303-4

  • Online ISBN: 978-3-030-33304-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation